Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. - Test2 - elhamkhani - TriplyDB

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

http://www.wikidata.org/entity/Q34539324

about

Burden of pediatric hepatitis C Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C.Hepatitis C virus infection in the human immunodeficiency virus infected patient.FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients.The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.Role of genetic polymorphisms in hepatitis C virus chronic infection.Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro, Brazil.Genetic predictors of the response to the treatment of hepatitis C virus infection.The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C.Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression.Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity.Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4.Lack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran.Individualization of chronic hepatitis C treatment according to the host characteristics.Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities.Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Investigations of interferon-lambda for the treatment of cancer.Associations between MTHFR Ala222Val polymorphism and risks of hepatitis and hepatitis-related liver cancer: a meta-analysis.Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.Profile of HIV subtypes in HIV/HBV- and HIV/HCV-coinfected patients in Southern Brazil.European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients.Interleukin-28B polymorphisms and hepatitis C virus clearance.IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients.The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis.

P2860

Q27025476-4DD2FB6D-2668-43EB-A62D-A36596C53E9F Q28547151-CCE8A235-F62B-4906-82FB-499B4D3752B3 Q33779801-68DDD873-8140-4773-8D5E-A00F6B1AA3C4 Q34113840-4AE658B7-3FAA-462C-9070-E08FBE491AFF Q34168504-C1FE0C18-AE45-4702-8315-E2ED942CD0B8 Q34474404-7879EA55-7EB9-4B7D-847E-B7C5BEB615FC Q34506224-91D76C22-58D4-45FD-A657-9CE2E9BE7A44 Q34604371-110B53AA-82CE-4E7D-A643-159E7E50ADFD Q34970209-686BFC9B-4576-46B6-85CC-5D2F34A9128F Q35146008-498E4E6D-C499-4F72-981F-F85D9C48A1FA Q35675852-0DCFDADE-6480-4443-BF13-65C9ABDB5EF5 Q35779058-EC94D1DE-2BEB-49C2-9BC5-9C109E56A6A2 Q35925546-DF6299E5-78D0-4486-AA0A-2C40C7243FBD Q36184217-6A663477-004E-4CB8-A44D-A8DA4E33262A Q36213126-44FB1204-4A66-4DED-8FBA-90C97E07A70D Q36257252-BB0CE69C-B454-4E9B-8928-D57D11BC0163 Q36402309-C2BECE80-1500-4247-A29F-D9FF0DF4BD23 Q36805359-282B2CED-1E60-492C-B119-333C5FB6C5D4 Q36852421-38B9FABD-B955-4645-A059-13F86AFAC830 Q37230823-D13CD692-D0D1-48C3-BE6C-892CE6E2904D Q37374059-8032238B-AFFD-48E3-AA84-38817AC8741B Q37385600-72D59112-6B00-4994-9265-DD502D27448D Q37643650-E8E628EB-0C13-44D1-AC22-FE2363E3C0C6 Q37654502-2348E0DE-35E6-4952-9720-A6DA2EC8D06A Q37678082-E2484760-77D2-4848-B3FF-8AE5865CE770 Q38136078-94EC86B4-AFEC-40E9-B701-D97E2D921591 Q38347596-B4869818-7A31-4B6B-BE58-B65BF6F5BB48 Q38403668-7146A36F-2870-46D0-8CB0-78FA1692FB2D Q38445623-61508EF2-9B5C-4C13-A8B0-CA7AF3F67E1C Q39910149-C04A9D3A-8C30-4234-8C5F-BD836596D253 Q40808386-1CF9427F-1A10-4448-822F-0B43A78700B8 Q41929282-E37C6A19-797D-47C6-A4DE-DAE1540725D4 Q42234661-67F68C15-55A7-48B0-A13E-6B3B5EAC7C73 Q42236605-92DC958A-3642-4FCB-B736-97856AA7C9B5 Q42242609-4365D802-52AC-47C8-A675-DAA4696DE919 Q42250948-21B18784-9504-4BD5-8C85-899C8D26D409 Q42264136-3BEC2F32-EFEE-4945-967F-A89A06BB13A9 Q43864701-AC387F5D-38AF-497A-ABBB-458A8CBB6C64

P2860

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

http://www.wikidata.org/entity/Q34539324

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Meta-analysis: implications of ...... for patients with hepatitis C.

@ast

Meta-analysis: implications of ...... for patients with hepatitis C.

@en

Meta-analysis: implications of ...... for patients with hepatitis C.

@nl

type

label

Meta-analysis: implications of ...... for patients with hepatitis C.

@ast

Meta-analysis: implications of ...... for patients with hepatitis C.

@en

Meta-analysis: implications of ...... for patients with hepatitis C.

@nl

prefLabel

Meta-analysis: implications of ...... for patients with hepatitis C.

@ast

Meta-analysis: implications of ...... for patients with hepatitis C.

@en

Meta-analysis: implications of ...... for patients with hepatitis C.

@nl

P1433

Q34539324-FB2E54DE-6DDE-43D1-9590-ACCE69119399

P1476

Q34539324-1CA72EDF-F37A-4054-A74A-D203C16310A1

P2093

Q34539324-0FA9A566-E128-4B9E-BBF3-5F9C90ACBC4B

Q34539324-26268BDD-B161-457F-9E08-0FCA1941B3BD

Q34539324-B53E98D7-5F67-43C1-879A-9441B64C353D

Q34539324-C5D8FBE5-3A6C-4AC1-98EE-DC3919323E6A

P2860

Q34539324-0192E5B2-F29A-4FA0-B222-88ADF141BCF9

Q34539324-0435CE2F-ED50-403D-9640-3668C03E62D4

Q34539324-065892CD-D8F2-480A-8337-BCBA9863C8AA

Q34539324-084AA03E-A02D-4494-A9C6-DE11A38CA998

Q34539324-09AD8051-A4EE-49F6-94BE-D17E09E41482

Q34539324-0F41B8BF-B5DC-46DA-A8F9-BFAB27A6EF5B

Q34539324-114CCC0F-EE7C-4FB5-AEF1-BDDDDACCFFF8

Q34539324-11F2A8AD-9CF0-4F08-9535-BEFD86DB801C

Q34539324-1663E6B9-0DD0-4CFC-B0C4-FB4DC46B3B96

Q34539324-18D2285D-2596-4605-B481-1C7B3051CA33

P2888

Q34539324-87CA7B38-87DD-4160-BE85-6A0AB0AE2F8F

P304

Q34539324-8A64E668-E52B-4EA8-9E1F-99FBF151C917

P31

Q34539324-BF62826C-F919-4941-ABCD-3C8D9A2C68A9

Q34539324-b9d958ad-88e5-4710-a89e-da593b455acc

P356

Q34539324-F2CF2251-3BE4-4AC0-A1C7-D80BBEAB5ED1

P407

Q34539324-5F21718D-1A7E-49BF-966F-6656D6363900

P478

Q34539324-DC4BFFE6-0A61-4DBB-A71A-92824DAA7567

P50

Q34539324-9ADAA9E2-303E-4849-93BC-00DB643F0D43

P577

Q34539324-4EC03160-D6AA-4C09-8A28-AF41CF85C8C7

P5875

Q34539324-8C90A2BA-701E-4A39-B1AB-07AEEA871DF6

P6179

Q34539324-244FC80E-EA7C-426D-A9BF-79779E1BCBF9

P698

Q34539324-9A99637A-EAA1-4A61-A8B4-8280209C5D38

P921

Q34539324-17C4E70C-F8ED-41FA-AB0B-02B6AA2250FF

Q34539324-5890FE53-E9A8-4881-B4FF-9B5E56572550

Q34539324-7320a317-27c7-438b-bd8a-ba0fc0c456a7

P932

Q34539324-055CC1AD-4841-4392-8281-DCB0206AFC16

P356

P1433

P1476

Meta-analysis: implications of ...... for patients with hepatitis C.

@en

P2093

Amanda Fernández-Rodríguez

http://www.w3.org/2001/XMLSchema#string

María A Jiménez-Sousa

http://www.w3.org/2001/XMLSchema#string

María Guzmán-Fulgencio

http://www.w3.org/2001/XMLSchema#string

Mónica García-Álvarez

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Genetic variation, classification and 'race'

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Statistical aspects of the analysis of data from retrospective studies of disease

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C

P2888

P304

6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1741-7015-11-6

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Salvador Resino

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234087990

http://www.w3.org/2001/XMLSchema#string

P6179

1040285883

http://www.w3.org/2001/XMLSchema#string

P698

23298311

http://www.w3.org/2001/XMLSchema#string

P921

P932

3570369

http://www.w3.org/2001/XMLSchema#string